All Stories

  1. Utilizing an Ex Vivo Skin Penetration Analysis Model for Predicting Ocular Drug Penetration: A Feasibility Study with Curcumin Formulations
  2. Development of transferosomes for topical ocular drug delivery of curcumin
  3. Mechanism of Ocular Penetration of Lipophilic Drugs from Lipophilic Vehicles
  4. Future Therapeutics: Targeting the NLRP3 Inflammasome Pathway to Manage Diabetic Retinopathy Development and Progression
  5. Tissue-based models for ocular permeability studies
  6. Systemic Inflammasome Biomarkers as Predictors of Diabetic Retinopathy Progression: Evidence from a Pilot Study
  7. Comprehensive Grading System for Experimental Autoimmune Uveitis in Mice
  8. Non-aqueous formulations in topical ocular drug delivery – A paradigm shift?
  9. Preclinical characterization of water-free cyclosporine eye drops – Factors impacting ocular penetration ex vivo and in vivo
  10. NLRP3 Inflammasome as a Potential Therapeutic Target in Dry Eye Disease
  11. Orally Delivered Connexin43 Hemichannel Blocker, Tonabersat, Inhibits Vascular Breakdown and Inflammasome Activation in a Mouse Model of Diabetic Retinopathy
  12. Characterization of NLRP3 Inflammasome Activation in the Onset of Diabetic Retinopathy
  13. Extracellular Vesicles as Biomarkers and Therapeutics for Inflammatory Eye Diseases
  14. Preparation and Characterisation of a Cyclodextrin-Complexed Mānuka Honey Microemulsion for Eyelid Application
  15. Preclinical confirmation of UVC efficacy in treating infectious keratitis
  16. Blocking connexin43 hemichannels prevents TGF‐β2 upregulation and epithelial–mesenchymal transition in retinal pigment epithelial cells
  17. Ocular Distribution of Papaverine Using Non-aqueous Vehicles
  18. Ex vivo evaluation of the influence of pH on the ophthalmic safety, antibacterial efficacy and storage stability of povidone‐iodine
  19. Differential Action of Connexin Hemichannel and Pannexin Channel Therapeutics for Potential Treatment of Retinal Diseases
  20. Formulation Considerations for the Management of Dry Eye Disease
  21. The influence of hyperglycemia on the safety of ultrasound in retinal pigment epithelial cells
  22. Connexin43 hemichannel block inhibits NLRP3 inflammasome activation in a human retinal explant model of diabetic retinopathy
  23. Tonabersat Inhibits Connexin43 Hemichannel Opening and Inflammasome Activation in an In Vitro Retinal Epithelial Cell Model of Diabetic Retinopathy
  24. Targeting connexin hemichannels to control the inflammasome: the correlation between connexin43 and NLRP3 expression in chronic eye disease
  25. Connexin43 hemichannels: A potential drug target for the treatment of diabetic retinopathy
  26. Depot formulations to sustain periocular drug delivery to the posterior eye segment
  27. Preclinical studies evaluating the effect of semifluorinated alkanes on ocular surface and tear fluid dynamics
  28. Ultrasound-responsive nanobubbles for enhanced intravitreal drug migration: An ex vivo evaluation
  29. Connexin43 hemichannel block protects against the development of diabetic retinopathy signs in a mouse model of the disease
  30. Brinzolamide–loaded nanoemulsions: ex vivo transcorneal permeation, cell viability and ocular irritation tests
  31. Intravitreal pro-inflammatory cytokines in non-obese diabetic mice: Modelling signs of diabetic retinopathy
  32. Intracellular oligonucleotide delivery using the cell penetrating peptide Xentry
  33. Hyaluronic acid coated albumin nanoparticles for targeted peptide delivery in the treatment of retinal ischaemia
  34. Effects of enzymatic degradation on dynamic mechanical properties of the vitreous and intravitreal nanoparticle mobility
  35. Micelle directed chemical polymerization of polypyrrole particles for the electrically triggered release of dexamethasone base and dexamethasone phosphate
  36. 3-Dimensionally ordered macroporous PEDOT ion-exchange resins prepared by vapor phase polymerization for triggered drug delivery: Fabrication and characterization
  37. Semifluorinated alkane based systems for enhanced corneal penetration of poorly soluble drugs
  38. Drug delivery to the lens for the management of cataracts
  39. The inflammasome pathway is amplified and perpetuated in an autocrine manner through connexin43 hemichannel mediated ATP release
  40. Erratum to “Ultrasound-mediated nanoparticle delivery across ex vivo bovine retina after intravitreal injection” [Eur. J. Pharm. Biopharm. 119 (2017) 125–136]
  41. Development of a novel stability indicating RP-HPLC method for quantification of Connexin43 mimetic peptide and determination of its degradation kinetics in biological fluids
  42. Immunohistochemical Characterization of Connexin43 Expression in a Mouse Model of Diabetic Retinopathy and in Human Donor Retinas
  43. Drug-device combination approaches for delivery to the eye
  44. Ultrasound-mediated nanoparticle delivery across ex vivo bovine retina after intravitreal injection
  45. Medicated ocular bandages and corneal health: potential excipients and active pharmaceutical ingredients
  46. Phase transition of a microemulsion upon addition of cyclodextrin – applications in drug delivery
  47. Overcoming ocular drug delivery barriers through the use of physical forces
  48. Preparation and evaluation of PLGA nanoparticle-loaded biodegradable light-responsive injectable implants as a promising platform for intravitreal drug delivery
  49. Randomised masked trial of the clinical safety and tolerability of MGO Manuka Honey eye cream for the management of blepharitis
  50. Preclinical development of MGO Manuka Honey microemulsion for blepharitis management
  51. Nanoparticle-loaded biodegradable light-responsive in situ forming injectable implants for effective peptide delivery to the posterior segment of the eye
  52. Tonabersat Prevents Inflammatory Damage in the Central Nervous System by Blocking Connexin43 Hemichannels
  53. Nanocarrier mediated retinal drug delivery: overcoming ocular barriers to treat posterior eye diseases
  54. Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies
  55. Hyaluronic Acid Coated Albumin Nanoparticles for Targeted Peptide Delivery to the Retina
  56. PLGA nanoparticles for intravitreal peptide delivery: statistical optimization, characterization and toxicity evaluation
  57. Ocular drug delivery—eye on innovation
  58. Azithromycin and Dexamethasone Loaded β-Glucan Films for the Treatment of Blepharitis
  59. Semi-fluorinated alkanes for topical delivery of Cyclosporine
  60. Stimuli-responsive systems for tuneable ocular drug delivery
  61. NLCs for Ocular Drug Delivery
  62. Ex vivo investigation of ocular tissue distribution following intravitreal administration of connexin43 mimetic peptide using the microdialysis technique and LC-MS/MS
  63. Modern approaches to the ocular delivery of cyclosporine A
  64. Light-responsivein situforming injectable implants for effective drug delivery to the posterior segment of the eye
  65. Nanoparticle cross-linked collagen shields for sustained delivery of pilocarpine hydrochloride
  66. Connexin43 in retinal injury and disease
  67. Cytotoxicity considerations and electrically tunable release of dexamethasone from polypyrrole for the treatment of back-of-the-eye conditions
  68. ZnO/PVP nanoparticles induce gelation in type I collagen
  69. In vitro and ex vivo corneal penetration and absorption models
  70. Highly porous Poly(3,4-ethylenedioxythiophene) prepared by vapor phase polymerization for biomedical applications
  71. Electrically-responsive implants for drug delivery to the posterior segment of the eye
  72. Development of gatifloxacin-loaded cationic polymeric nanoparticles for ocular drug delivery
  73. Neuroprotection in the treatment of glaucoma – A focus on connexin43 gap junction channel blockers
  74. Sustained intravitreal delivery of connexin43 mimetic peptide by poly(d,l-lactide-co-glycolide) acid micro- and nanoparticles – Closing the gap in retinal ischaemia
  75. Ocular delivery systems for topical application of anti-infective agents
  76. Intravitreal injection of lipoamino acid-modified connexin43 mimetic peptide enhances neuroprotection after retinal ischemia
  77. Electro-responsive macroporous polypyrrole scaffolds for triggered dexamethasone delivery
  78. Implants for drug delivery to the posterior segment of the eye: A focus on stimuli-responsive and tunable release systems
  79. Dendrimers for gene delivery - a potential approach for ocular therapy?
  80. Cytotoxicity and Vitreous Stability of Chemically Modified Connexin43 Mimetic Peptides for the Treatment of Optic Neuropathy
  81. Injectable implants for the sustained release of protein and peptide drugs
  82. Synergistic effect of chemical penetration enhancer and iontophoresis on transappendageal transport of oligodeoxynucleotides
  83. Improved Corneal Wound Healing through Modulation of Gap Junction Communication Using Connexin43-Specific Antisense Oligodeoxynucleotides
  84. Characterization and evaluation of β-glucan formulations as injectable implants for protein and peptide delivery
  85. Evaluation of Fluorescence Resonance Energy Transfer Approaches as a Tool to Quantify the Stability of Antisense Oligodeoxynucleotides
  86. Environment-sensitive polymers for ophthalmic drug delivery
  87. Ion-ActivatedIn SituGelling Systems for Antisense Oligodeoxynucleotide Delivery to the Ocular Surface
  88. Role of gap junctions in chronic pain
  89. In vitro release characteristics and cellular uptake of poly(D,L-lactic-co-glycolic acid) nanoparticles for topical delivery of antisense oligodeoxynucleotides
  90. Comparison of ion-activated in situ gelling systems for ocular drug delivery. Part 2: Precorneal retention and in vivo pharmacodynamic study
  91. Comparison of ion-activated in situ gelling systems for ocular drug delivery. Part 1: Physicochemical characterisation and in vitro release
  92. Ocular Drug Delivery
  93. Imaging Techniques and their Role in Dosage form Design and Drug Delivery Research
  94. Ocular Drug Delivery